Ikena Oncology Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IKENA ONCOLOGY, INC. | ||
| Date: March 6, 2025 | By: | /s/ Mark Manfredi |
|---|---|---|
| Mark Manfredi, Ph.D. | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Mark Manfredi | President, Chief Executive Officer and Director | March 6, 2025 |
| Mark Manfredi, Ph.D. | Principal Executive Officer | |
| /s/ Jotin Marango | Chief Financial Officer, Chief Operating Officer and Head of Corporate Development | March 6, 2025 |
| Jotin Marango, M.D., Ph.D. | Principal Financial Officer and Principal Accounting Officer | |
| /s/ Owen Hughes | Director | March 6, 2025 |
| Owen Hughes | ||
| /s/ David Bonita | Director | March 6, 2025 |
| David Bonita, M.D. | ||
| /s/ Iain D. Dukes | Director | March 6, 2025 |
| Iain D. Dukes, D.Phil. | ||
| /s/ Jean-François Formela | Director | March 6, 2025 |
| Jean-François Formela, M.D. | ||
| /s/ Maria Koehler | Director | March 6, 2025 |
| Maria Koehler, M.D., Ph.D. | ||
| /s/ Otello Stampacchia | Director | March 6, 2025 |
| Otello Stampacchia, Ph.D. | ||
| /s/ Richard Wooster | Director | March 6, 2025 |
| Richard Wooster, Ph.D. | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss | F-4 |
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.